



Cite this: *Chem. Soc. Rev.*, 2018, 47, 9015

## Antimicrobial glycoconjugate vaccines: an overview of classic and modern approaches for protein modification

Francesco Berti \* and Roberto Adamo \*

Glycoconjugate vaccines obtained by chemical linkage of a carbohydrate antigen to a protein are part of routine vaccinations in many countries. Licensed antimicrobial glycan–protein conjugate vaccines are obtained by random conjugation of native or sized polysaccharides to lysine, aspartic or glutamic amino acid residues that are generally abundantly exposed on the protein surface. In the last few years, the structural approaches for the definition of the polysaccharide portion (epitope) responsible for the immunological activity has shown potential to aid a deeper understanding of the mode of action of glycoconjugates and to lead to the rational design of more efficacious and safer vaccines. The combination of technologies to obtain more defined carbohydrate antigens of higher purity and novel approaches for protein modification has a fundamental role. In particular, methods for site selective glycoconjugation like chemical or enzymatic modification of specific amino acid residues, incorporation of unnatural amino acids and glycoengineering, are rapidly evolving. Here we discuss the state of the art of protein engineering with carbohydrates to obtain glycoconjugate vaccines and future perspectives.

Received 12th June 2018

DOI: 10.1039/c8cs00495a

rsc.li/chem-soc-rev

### Key learning points

- The covalent linkage with proteins is fundamental to transform carbohydrates, which are *per se* T-cell independent antigens, in immunogens capable of evoking a long-lasting T-cell memory response.
- Principal strategies for conjugation of bacterial polysaccharides with the protein carrier used in licensed glycoconjugate vaccines.
- Modern methods for site selective glycoconjugation comprise chemical or enzymatic modification of specific amino acid residues, incorporation of unnatural amino acids and glycoengineering.
- Importance of the definition of the polysaccharide portion (epitope) responsible for the immunological activity in the design of glycoconjugate vaccines.
- How information from structural studies, strategies for carbohydrate production and protein modification can be combined in order to maximize the immunological activity of glycoconjugate vaccines.


## 1. Introduction

Vaccination is an effective means to reduce death and morbidity caused by infectious diseases. Over the years, the practise of vaccination with live attenuated bacteria, as originally conceived by Jenner to treat smallpox in 1796 and later developed by Pasteur, has most often left the stage to safer subunit vaccines, which achieve protection by focusing the immune response on one or a few selected antigens. Among these, the structurally unique carbohydrates coating the surface of bacteria have become an optimal target for vaccine development.<sup>1</sup> Since the 1970s, it has been evident that the purified capsular polysaccharide from *Streptococcus pneumoniae*, *Haemophilus influenzae* type b (Hib) and

*Neisseria meningitidis* infections could be used for the prevention of infections in adults. However it was only in the 1980s that revisiting the concept of sugar conjugation to a carrier protein, first introduced by Avery and Goebel in the early 1930s,<sup>2</sup> carbohydrate-based vaccines effective also in infants could be developed.

Currently, glycoconjugate vaccines, as the product of chemical linkage of a carbohydrate antigen to a protein is typically termed, are part of routine vaccinations in many countries. The covalent linkage between sugars and proteins enables bacterial surface carbohydrates, which are *per se* T-cell independent antigens, to be capable of evoking a long-lasting T-cell memory response. This type of response is accompanied by the differentiation of polysaccharide-specific B cells to plasma cells. Reinfection with the pathogen or boosting, in the case of a vaccine results in proliferation of plasma cells and maturation of high-affinity

GSK, Via Fiorentina 1, 53100 Siena, Italy. E-mail: roberto.x.adamo@gsk.com, francesco.x.berti@gsk.com



antibodies that can eliminate both the disease and the carriage of bacteria in the immunized individuals.

Following the success of capsular polysaccharide derived vaccines, the practise of protein conjugation has been extended to other classes of carbohydrates, including O-antigens, exopolysaccharides and teichoic acids.<sup>1</sup>

Furthermore, emergence of bacterial species resistant to antibiotic treatment, as stressed out by recent WHO and CDC reports, is generating a call for novel, improved, fast acting vaccines.<sup>1</sup>

While the commercially available vaccines (Table 1) were obtained through isolation of the polysaccharides from pathogens and were developed primarily based on empiric evidence, in the last twenty years there has been a rapid evolution in the approaches to obtain more defined carbohydrate antigens of higher purity.

In parallel, novel technologies for protein modification with glycans have emerged, in some cases inspired by the conjugation methods of small molecules to therapeutic monoclonal antibodies.<sup>3</sup> Combination of these techniques and structural approaches for the definition of the polysaccharide portion (epitope) responsible for the immunological activity has the potential to aid a deeper understanding of the mode of action of glycoconjugates and to lead to the rational design of more efficacious and safer vaccines.

Here we discuss the state of the art of protein engineering with carbohydrates to obtain glycoconjugates vaccines and future perspectives.

## 2. The construction of glycoconjugate vaccines

### 2.1 Why conjugation is needed

Polysaccharides present on the surface of capsulated bacteria are composed of many identical repeating units. Each repeating

unit can be a single monomer (homopolymer) or a combination of few monomers (heteropolymer). In adult, purified polysaccharides stimulate B-cell differentiation into plasma cells producing antibodies by cross-linking the B-cell receptor. In infant, this mechanism is not fully mature and polysaccharides fail to trigger a T cell memory response.<sup>4</sup> However, when a polysaccharide is conjugated to a carrier protein, peptides deriving from their intracellular digestion enter the cavity of the Major Histocompatibility Complex Class II (MHCII) and are re-exposed for engagement of the T cell receptor.<sup>4</sup> In one example T cell recognizing specifically the carbohydrate portion of a glycopeptide anchored to MHCII have been found.<sup>5</sup> T cells in turn trigger B cells to specialized and produce highly specific antibodies that can activate cascade reactions for bacterial destruction.<sup>4</sup>

While the necessity of a covalent linkage between carbohydrate and protein is challenged by some studies using alternative systems such as liposomes for co-delivery of the two components,<sup>6</sup> licensed vaccines are all based on the concept of covalent conjugation. This tutorial focuses only on glycan-protein conjugates and methods for protein conjugation. For a broader overview on other types of glycoconjugates based on peptides and fully synthetic scaffolds we suggest reading ref. 7 and references therein.<sup>7</sup>

### 2.2 Carbohydrate production

For the manufacturing of licensed vaccines, purified polysaccharides are used natural or size-reduced through mechanical (*i.e.* microfluidization) or chemical (*i.e.* acidic hydrolysis, hydrogen peroxide) treatments. The size reduction of polysaccharide chains results in more defined oligosaccharide populations and reduce the density/viscosity of those compounds in aqueous solution facilitating the chemical coupling to the protein carrier.



**Francesco Berti**

*Francesco Berti earned his PhD in Chemical Sciences in 2002 from the University of Siena (Italy), working on magnetic resonance technologies. During his PhD studies, he joined Chiron where he contributed to the preparation and structural characterization of meningococcal ACW<sub>135Y</sub> polysaccharide-protein conjugate vaccines, which was eventually licensed in US and Europe in 2010 (Menveo<sup>®</sup>). His career continued within the same company which was acquired first*

*by Novartis and later by GSK, where he was appointed Head of Vaccine Chemistry Formulation Department and Head of Antigen Design. Currently he is Scientific Director at the Technical R&D. Over the last 12 years he has been working on the research and development of several carbohydrate-based vaccines to combat a variety of infective diseases.*



**Roberto Adamo**

*Roberto Adamo obtained his PhD in Pharmaceutical Science from the University of Catania (Italy) in 2003, with a thesis on the synthesis of biologically relevant inositols. He two post-doctoral fellowships at the NIH in Bethesda (USA), under the supervision of Dr P. Kovac, and in the group of Prof. J. P. Kamerling at the Utrecht University (The Netherlands). In 2007 he joined Novartis vaccines where he was later appointed Head of the Carbohydrate Chemistry*

*Laboratory, and leader of the conjugation & synthesis platform. Following the company acquisition by GSK, he became preclinical representative leader of the conjugation platform that he is currently leading. His research interests focus on the synthesis of glycans, glycoconjugates and glyconanoparticles to be used for carbohydrate-based therapeutics.*



Table 1 Glycoconjugate vaccines licensed by FDA<sup>a</sup>

Pathogen	Commercial trade name/manufacturer	Carrier protein	Saccharide chain length	Conjugation chemistry
<i>Haemophilus influenzae</i> type B	ActHIB/Sanofi Pasteur (monovalent) (Multivalent formulations also containing Hib conjugate: pentacel, DTaP and inactivated poliovirus; Hexacima/Hexyon, DtaP, hepatitis B rDNA and inactivated poliomyelitis)	TT	Native polysaccharide	Information not available
	Hiberix/GSK vaccines	TT	Size-reduced polysaccharide	Information not available
	Quinvaxem/GSK vaccines (multivalent formulation containing DTP, HepB and Hib conjugate)	CRM <sub>197</sub>	Depolymerized polysaccharide	Active ester chemistry
<i>Neisseria meningitidis</i> serogroup C	PedvaxHIB/Merck	OMPC	Native polysaccharide	Information not available
	NeisVac-C/Pfizer	TT	Native polysaccharide	Reductive amination
	Meningitec/Nuron Biotech	CRM <sub>197</sub>	Native polysaccharide	Reductive amination
	Menjugate/GSK vaccines	CRM <sub>197</sub>	Depolymerized polysaccharide	Active ester chemistry
<i>Neisseria meningitidis</i> serogroup CY	Menitorix/GSK vaccines (with Hib)	TT	Size-reduced polysaccharide	Information not available
	MenHibrix/GSK vaccines (with Hib)	TT	Size-reduced polysaccharide	Information not available
<i>Neisseria meningitidis</i> serogroup ACWY	Menactra/Sanofi Pasteur	DT	Depolymerized polysaccharide	Information not available
	Menveo/GSK	CRM <sub>197</sub>	Depolymerized polysaccharide	Active ester chemistry
	Nimenrix/Pfizer	TT	Size-reduced polysaccharide	Active ester chemistry
<i>Streptococcus pneumoniae</i> serogroup 4, 6B, 9V, 14, 18C, 19F, 23F	Prevnar/Pfizer	CRM <sub>197</sub>	Native polysaccharide	Reductive amination
<i>Streptococcus pneumoniae</i> serogroup 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F	Synflorix/GSK	NTHi PD, DT, TT	Size-reduced polysaccharide	Reductive amination
<i>Streptococcus pneumoniae</i> serogroup 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F	Prevnar13/Pfizer	CRM <sub>197</sub>	Native polysaccharide	Information not available

<sup>a</sup> <https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm> and EMA [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar\\_search.jsp&mid=WC0b01ac058001d124](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124) up to 31 May 2018.

Chemical synthesis has been successful for large scale production of the Hib antigen, which was made by a one-step poly-condensation reaction based on the H-phosphonate chemistry.<sup>8</sup>

At preclinical and clinical level, there are a plethora of methods currently used to achieve oligosaccharide synthesis. The pentadecasaccharide of *Shigella flexneri* 2a has been led to Phase-1 clinical trial after intensive synthesis optimization.<sup>9</sup> Approaches for speeding up the carbohydrate antigen production include the use of solid-phase automated synthesis, iterative protocols or combined chemo-enzymatic strategies.<sup>10–12</sup> Typically the selection of the more suited approach for a target structure is still a result of extensive experience in the field. Among these technologies, the number of structures achieved by automated synthesis is rapidly growing. This method so far can deliver production of oligosaccharide at a scale sufficient for preclinical testing, while subsequent phases of vaccine manufacturing would require process development.

*E. coli* glycoengineering for *in vivo* expression of glycoproteins is a technology able to provide the oligosaccharide directly linked to the carrier protein and will be discussed more in depth below.

### 2.3 Protein selection

Carrier proteins need to provide T cell epitopes and present a sufficient number of surface exposed functional groups

for conjugation. As shown in Table 1, five carrier proteins (TT, Tetanus Toxoid; DT, Diphtheria Toxoid; CRM<sub>197</sub>, Cross Reacting Material 197; NTHi PD, non typeable *H. influenzae* protein D; OMPC, outer membrane protein complex) have been used for all licensed conjugate vaccines.<sup>1</sup> The toxoids DT and TT are obtained from the respective toxins by chemical detoxification with formaldehyde, while CRM<sub>197</sub> is a nontoxic mutant of diphtheria toxin isolated from the supernatant of *Corynebacterium diphtheriae* C7(b197) tox(–) strain bacterial growths or produced recombinantly in *E. coli*. Also NTHi PD is expressed in *E. coli* as recombinant protein. Other proteins such as recombinant *Pseudomonas aeruginosa* exotoxin A (rEPA) have been used at preclinical and clinical level.<sup>13</sup>

### 2.4 Conjugation chemistry

For conjugation, sugars and proteins are typically modified to achieve the chemoselective coupling reaction. Characteristics of the final conjugates as modification pattern of the sugar (*e.g.* O-acetylation), saccharide length, saccharide/protein ratio and type of carrier protein, conjugation chemistry and linkers eventually used for coupling are relevant for the immunogenicity. These features depend on the approaches used for the preparation of glycoconjugates. Below are discussed the most common methods used for this scope.

**2.4.1 Strategies for sugar modification.** Sugars can be activated for conjugation in non selective manner (see ref. 14



and references therein), like by random reaction of hydroxyls with (i) cyanilating agents to generate cyanide groups for reaction with amines or hydrazines, or (ii) carboimidazole to introduce carboxyl moieties for further extension with ethylenediamine<sup>14</sup> (Fig. 1A).

More chemoselective methods are based on periodate oxidation of (i) *cis*-diols in the sugar ring or at the glycerol moiety of sialic acid residues to generate aldehydes or (ii) activation of carboxyl groups of sialic or acid uronic residues (Fig. 1B).<sup>14</sup>

Linkers can be used to insert chemical handles for conjugation, reducing steric hindrance between protein and saccharide. Generated aldehydes or end terminal aldehydes from oligosaccharides are typically reacted with the  $\epsilon$ -amine of lysine residues by reductive amination. Alternative reductive amination can be performed with ammonium salts to provide an amine ready for coupling or derivatized with di-hydrazide spacers (Fig. 1C).<sup>14</sup> Inserted amines can be reacted directly with carboxylic acids of the protein or coupled to a variety of bifunctional linkers to incorporate squaric ester, maleimide, thiol, azide or alkyne moieties to aid conjugation.

Synthetic sugars offer the advantage of bearing reactive groups such as amines (for further modification, *vide supra*), thiols or alkenes for aldehyde generation (Fig. 1D).




Fig. 1 Classic methods for sugar modification.




Fig. 2 Methods for random conjugation.

**2.4.2 Protein conjugation.** Licensed glycoconjugate vaccines are obtained by random conjugation to lysine (Fig. 2A), aspartic or glutamic amino acid residues (Fig. 2B) that are generally abundantly exposed on the surface due to their hydrophilic character. Sometimes protein are modified with linkers exposing chemical groups for conjugation, including hydrazides, maleimides, azides, alkynes to couple with sugar residues activated as above described.

### 3. Site-selective approaches in glycoconjugation

More defined glycoconjugates than those currently licensed are attractive candidates to have well characterized products and to correlate the immunogenicity to a precise attachment site.<sup>15</sup> For a more extensive review of this topic we refer the readers to the ref. 16. Selective approaches appear more compatible with protein used with dual role of antigen and glycan carrier. Pathogen related carrier proteins could be a way to counteract possible reduced immune response against glycoconjugates due to repetitive administration of the same carrier protein.<sup>16</sup>

Four major approaches for site selective protein engineering have found application to glycoconjugation: chemical modification of amino acid residues, enzyme catalysed conjugation, incorporation of unnatural amino acids and glyco-engineering.<sup>3</sup>



Site selective reactions exploit the specific reactivity of certain amino acids residues in the context of the protein sequence.

Traditional conjugation methods are addressed to the very abundant lysine or aspartic/glutamic acid residues. Because of their ionic character these residues are well exposed on the protein surface. On the opposite, their high reactivity renders challenging the control of the conjugation site.

In particular, the high nucleophilicity of the amine in the K side chain is probably the most common feature employed for conjugation. The reactivity of lysine depends not only on solvent/reagent accessibility but also on the relative amino acid contour and pH. In some cases preferentiality for some lysine residues compared to others caused by the better exposition has been observed.<sup>17</sup> Very recently it has been shown that at slightly basic pH the lysine with the lowest  $pK_a$  is the kinetically favoured residue for reaction.<sup>18</sup>

### 3.1 Chemical or enzymatic modification of natural amino acids

Site selective coupling is typically achieved by targeting highly nucleophilic cysteine residues either naturally present or genetically installed at the protein surface. Both native and engineered cysteine residues are known to react rapidly with a variety of electrophilic reagents, including sugars derivatives with thio or selenoether, maleimides and haloalkyl groups (Fig. 3A).<sup>19</sup> Alternatively, cysteine can be elongated with an electrophilic chemical handle, like a bromooxetane<sup>20</sup> or a bromoisobutylene<sup>21</sup> for following halogen displacement with a thiosugar. Cysteine can also be converted into dehydroalanine to undergo Michael addition of thiosugars<sup>22</sup> or aza-Michael ligation of a wide-range of *N*-nucleophiles, including carbohydrates bearing an alkylamine linker.<sup>23</sup>

Cysteine residues involved in disulfide bond formation usually plays a role in stabilizing protein tertiary structure. It is possible to temporarily cleave the disulfide bond to then staple the two cysteines through a short covalent bridge (Fig. 3B). This bridge can be functionalized with a chemical group for glycan coupling, such as a ketone.<sup>24</sup>

Tyrosine residues are much less abundant and exposed than lysine residues so they can be more selectively targeted for glycoconjugation (Fig. 3C). To this end, triazolinediones has been exploited to react with the phenol ring of Y.<sup>25</sup> This reaction requires the use of tris(hydroxymethyl)aminomethane (Tris) buffer as scavenger for the isocyanates formed by the *in situ* degradation of the triazolidinones in order to direct the reaction to Y rather than to K residues.<sup>26</sup>

Modification of K, Q and G residues can be also selectively achieved by enzymatic methods.<sup>27</sup> In particular, enzymes can react with specific residues incorporated in a short amino acid tag which can be introduced either on the protein or on the sugar to be conjugated. Among these enzymes, transglutaminases (Tgases, Fig. 3D) are a family of widely expressed enzymes that have been used to label Q<sup>28</sup> or K.<sup>29</sup> Sortases from *Staphylococcus aureus* or *Streptococcus pyogenes* have been successfully applied

for conjugation to an N-terminal (G) $n$  ( $n \geq 3$ ) or C-terminal LPXTG tag.

It is worth considering that while tyrosine modification allows conjugation at more than one connectivity point selected among the naturally present residues, methods based on protein engineering with cysteine or incorporation of a tag for enzymatic transglutamination offer a larger flexibility in directing the conjugation to desired domains. However, a limitation often associated with the expression of proteins engineered with multiple cysteines is the tendency to aggregation which can dramatically decrease the production yield.

### 3.2 Unnatural amino acids

Proteins incorporating unnatural (*i.e.* not naturally found or encoded) amino acids (uAAs) in their sequence can be expressed through a modified translational machinery that include a specific codon, a tRNA recognizing the codon and a tRNA synthetase specific for the target uAA.<sup>30</sup> Among other possible expression systems, *E. coli* can be engineered to increase the production of the mutated protein. This combined with a large variety of uAAs currently available can expand the tools for protein conjugation. Inverse demand Diels–Alder reaction between tetrazine and genetically encoded *trans*-cyclooctene (TCO) and bicyclononyne (BCN) modified uAAs has been harnessed for conjugation of sugar moieties directly in cellular medium or in lysates.<sup>31</sup> Proteins engineered with uAAs can be produced also from *E. coli* derived cell free extract. Sutrovax has developed a proprietary system termed XtractCF<sup>+</sup> for production of proteins modified with functional groups for click chemistry with carbohydrates (Fig. 3E).<sup>32</sup>

### 3.3 Glycoengineering

The *in vivo* production of glycoproteins through the so-called protein glycan coupling technology has recently found application for production of a variety of glycoconjugates.<sup>33</sup> This approach is based on the N-linked glycosylation system from *Campylobacter jejuni* that can be functionally expressed in *E. coli* and the ability of *E. coli* to synthesize heterologous polysaccharides on its glycosyl carrier lipid. To deliver a target glycoprotein *E. coli* is engineering with (i) the genome clusters encoding for the desired bacterial polysaccharide, (ii) the oligosaccharyl transferase PglB from *Campylobacter jejuni* and (iii) a plasmid encoding for the carrier protein carrying the *N*-glycosylation consensus sequences D/E-N-X-S/T, where X can be any amino acid except proline (Fig. 3F).<sup>34</sup> During the expression, pathogen glycans repeating units are first assembled in the cytoplasm anchored to a lipid carrier (undecaprenyl-pyrophosphate, Und-PP), and then flipped across the cytoplasmic membrane, typically by an ATP-binding cassette (ABC) transporter. In the periplasmic space, a polymerase (Wzy) builds up the sequence on the lipid carrier, and finally PglB transfers the resulting lipid linked oligosaccharides (LLO) to the asparagine residues of the *N*-glycosylation consensus sequence incorporated into the carrier protein. PglB is a promiscuous enzyme, but with higher preferentiality for hexosamines.






Fig. 3 Approaches for selective glycoconjugation. CuAAC = copper(II) catalyzed azide alkyne cycloaddition; SPAAC = strain promoted azide alkyne cycloaddition. SPAAC could deliver other isomers in addition to the depicted products.

## 4. Effect of the glycoconjugate design on the immunogenicity

### 4.1 Glycan epitopes

In general, minimal antigenic determinant of polysaccharides (meaning the portion which is interacting with antibodies) are defined oligosaccharides, which can structurally vary from a short linear disaccharide, as for *Vibrio cholerae* O1,<sup>35</sup> up to a

more complex hexasaccharide as observed for type III polysaccharide of Group B *Streptococcus* (GBS)<sup>36</sup> or even a non-saccharide, as in the case of *S. flexneri* serotype 2a O-antigen.<sup>37</sup> Branching points determining structural rigidity seems relevant in these epitopes as observed for pneumococcal type 14 repeating unit and GBS type III polysaccharide.<sup>36,38</sup>

How these glyco-epitopes influence stimulation of B cells is still not clear, however it is assumed that oligosaccharides long



enough to fill antibody binding sites are more likely to elicit antibodies reactive with the corresponding polysaccharides. The binding pocket of the variable regions of antibodies can interact with an area that could differ depending on the tridimensional structure that polysaccharides can acquire (e.g. helical conformations).<sup>39</sup>

The shape of the glycoconjugates and the way the glyco-epitopes are presented to the immune system are influenced particularly by some of the glycoconjugates' characteristics, specifically saccharide length, saccharide/protein ratio and conjugation chemistry. These factors interact in a strictly interconnected manner and affect the final immunological activity. This is well exemplified by an early study in infants where Hib polysaccharide fragments with average chain length 8 or 20 repeat units (average Degree of Polymerization, avDP8 and avDP20) were conjugated to DT *via* reductive amination by incorporating 2 and 3 sugar moieties per protein molecule, respectively. The avDP8 oligomer elicited poorer anti carbohydrate response than the avDP20.<sup>40</sup> However, in a follow up study, ~4.5 moieties of an end terminally activated DP7 oligosaccharide were conjugated to CRM<sub>197</sub>, resulting comparably immunogenic to the previously tested avDP20,<sup>41</sup> indicating that a higher level of glycosylation could compensate the chain length. Years later, an avDP8 was chemically synthesized and conjugated to TT to obtain the first licensed glycoconjugate based on a synthetic antigen.<sup>8</sup> More recently a Hib tetramer has been shown to possibly be a sufficient length for immunogenicity in the animal model which explains the immunological activity of DP7.<sup>42</sup>

#### 4.2 Different types of site-selective glycoconjugates currently available

Heterogeneous polysaccharides generally ensure exposition of a sufficient number of sugar epitopes along the carbohydrate chain to trigger B cells and promote T cell activation. However, their characterization is not trivial. Saccharide/protein ratio is described in terms of w/w and it is challenging to define the number of carbohydrate moieties linked to each molecule of carrier protein, therefore structure-immunogenicity relationship is not straightforward.

Different designs can help to better correlate the immunogenicity with glycoconjugates characteristics (Table 2).

Polysaccharides linked to preactivated tyrosine had allowed directing the conjugation to few predetermined sites, generating

more defined conjugates presenting multiple protein copies along the carbohydrate chain (Fig. 4A).

Capsular polysaccharides from GBS type II and V, a pathogen responsible for neonatal infections, have been coupled by strain promoted azide alkyne cycloaddition (SPAAC) to the three-four more exposed tyrosine residues of the pathogen related proteins GBS80 or GBS67, respectively.<sup>43,44</sup> The immunogenicity of the tyrosine directed GBS type II polysaccharide-GBS80 and GBS type V polysaccharide-GBS67 conjugates was shown non inferior to the corresponding CRM<sub>197</sub> conjugates.<sup>43,44</sup>

Anti-glycan and anti-protein antibodies were effective in inducing bacterial killing *in vitro* of strain expressing either the capsular polysaccharide or the pilus protein in comparable manner to random conjugation to the same proteins but with the advantage in terms of characterization of predetermined connectivity.<sup>44,45</sup> For GBS type V polysaccharide conjugation, the thiol-maleimide addition was compared to SPAAC showing to provide an efficacious vaccine, without production of anti-linker antibodies that are conversely induced by the linkers for click chemistry.

Expression in cell free derived *E. coli* extract of the carrier proteins modified with uAAs is being used by Sutrovax for the development of a conjugate vaccine against multiple pneumococcal strains.

End terminal linkage of semisynthetic or synthetic carbohydrates allows for a radial exposition of the glycan epitopes. In this case, the number of conjugated carbohydrates can be more accurately determined.

Conjugation of large polysaccharides to one connectivity has been achieved by microbial transglutaminase (mTGase) catalysed lysine modification and disulfide stapling.<sup>24,44</sup> In the first case basic pH was key to achieve selectivity at K37/39 of CRM<sub>197</sub> with the *Salmonella* O-antigen modified with a ZQG azido spacer (with Z = Cbz). At acidic pH the additional site K33 was modified.

Disulfide rebridging was successful to modify selectively C186-C201, the more exposed of the two S-S bonds of CRM<sub>197</sub>. This disulfide was reduced by TCEP for incorporation of 1,3-dichloroacetone which was then extended with a bifunctional aminoxy-azide linker to form an oxime. The azide was then clicked with the *Salmonella* O-antigen modified with a cyclooctene-cyclopropane spacer.<sup>24</sup> Interestingly the stapled conjugate showed superior immunological activity than the one at K37/39, suggesting a possible role of the conjugation site in the vaccine efficacy which deserves further elucidation.

Table 2 General features of the different glycoconjugates' designs

Carbohydrate source	Conjugation	Carbohydrate length	Saccharide moieties/protein	Conjug. site
Synthesis	Random	1 (or subunit)-3 repeating units from heteroPS	Variable, generally 3–25	K
Synthesis	Selective	Short oligosaccharide	1 4	C, pAMF Y
Sized polysaccharide	Random	5–50 repeating units	Variable	K
<i>E. coli</i> expression	Selective	10–20 repeating units	1–2	N
Native polysaccharide	Random	70–200 repeating units	Undefined	K, A/E
Native polysaccharide	Selective		1 4	K, C-C pAMF Y






Fig. 4 Summary of the different designs for glycan–protein conjugate vaccines.

Following studies on the carrier protein CRM<sub>197</sub> showed that the selective installation of an oxetane motif on the disulfide bridge enabled stabilization of folded structures and resulted in enhanced immunogenicity of the protein as antigen.<sup>46</sup>

Glycoengineering has been used by LimmaTech Biologicals (former GlycoVaxyn) to access to a number of structurally different glycoproteins, termed as bioconjugates to differ from chemical conjugates. The biosynthesized bacterial oligosaccharides vary from O-antigens (*Salmonella enterica*, *Shigella* spp, *E. Coli* LPS) or capsular polysaccharides (*S. aureus* serotype 5 or 8 CPS and *S. pneumoniae*).<sup>1</sup> Typically, these conjugates are characterized by medium length heterogeneous oligosaccharides linked to one or two tags genetically inserted in the protein carrier (Fig. 4B). For example, the conjugate against *Shigella dysenteriae* was composed by an O-antigen with a length of 13–20 repeating.<sup>13</sup> For the expression of the *E. coli* O121 O-antigen, which was obtained with the aim of mimicking the structurally similar polysaccharide from *Salmonella typhi*, two N-glycosylation sites were inserted.<sup>47</sup> Glycosylation occurred preferentially at one site with an average of 12 repeating units. To date the most used protein carrier is rEPA, although pathogen related carrier proteins have been also employed, such as *S. aureus*  $\alpha$  toxin Hla which was conjugated to capsular oligosaccharides from the same bacterium.<sup>48</sup>

Bioconjugate vaccine candidates are at a more advanced stage of development compared to other approaches. Vaccines against *S. dysenteriae* O1 and *S. flexneri* 2a,<sup>49</sup> and extra intestinal pathogenic *E. coli* have completed Phase-1 clinical trials showing to be safe and promising immunogenicity.<sup>50</sup>

Glycoconjugates with defined sugars at the more exposed tyrosines of the carrier protein have produced by GSK vaccines (former Novartis Vaccines & Diagnostics) and Novartis Institutes for Biomedical Research (NIBR) by tyrosine ligation (Fig. 4C).<sup>26</sup> The genetically detoxified diphtheria toxin mutant CRM<sub>197</sub>, a protein component of numerous licensed vaccines, was first modified primarily at Y27, Y46, Y358 and Y380, with an alkyne linker for CuAAC of a  $\beta$ -(1,3)-glucan hexasaccharide bearing an azide spacer. Insertion of double copies of the  $\beta$ -(1,3)-glucan antigen for each targeted tyrosine residues was also achieved.<sup>51</sup>

These two Y-directed conjugates constructs induced in mice comparable immune response than a CRM<sub>197</sub> conjugate of laminarin composed of a long heterogeneous  $\beta$ -(1,3)-(1,6)-glucan attached randomly to K residues, known to be highly protective against systemic and mucosal *C. albicans* infections.

Fully homogeneous products with one saccharide chain and connectivity to the protein (Fig. 4C) have been made by Davis and coworkers through coordinated carbohydrate synthesis of a thiol polyramnoside from *Klebsiella pneumoniae* O-antigen and following addition to the selenenylsulfide preactivated cysteine of the subtilisin mutant protein S156C.<sup>19</sup>

Production of the malaria antigen Pfs25 bearing the uAA *p*-azidomethyl phenylalanine (pAMF) at the C-terminus through the Sutrovax platform has recently been used for generating a conjugate with dibenzocyclooctyne (DBCO) derivatized glycan core of malaria GPI using strain promoted click chemistry. The Pfs25–GPI conjugate induced in mice significantly higher titers compared to the unconjugated protein, and purified anti Pfs25–GPI IgGs were able to block transmission of parasites to mosquitoes.<sup>32</sup>





While fully homogeneous conjugates would allow precise correlation of immunogenicity to length and attachment site, only few studies are available and the optimal carbohydrate size for these constructs is still unknown.

There is no simple general rule to predict the ideal saccharide/protein molar ratio in these vaccines. It has been postulated that a high level of protein modification could be needed for conjugation of short oligomers in order to elicit an optimal immune response, while a lower modification level could be sufficient for longer oligosaccharides.<sup>52</sup> Indeed glycosylation degrees of 8–10 sugar moieties have been shown sufficient to provide robust immune response to single repeating units<sup>32</sup> or even subunit epitopes, as recently shown for a *S. pneumoniae* type 1 trisaccharide epitope.<sup>53</sup>

In a recent work, glycosylation degrees varying from 5 to 26 were tested for the random conjugation of a pentadecasaccharides from *S. flexneri* 2a to TT, and a trend of increased anti-carbohydrate antibody levels was observed going up from 5 to 17 carbohydrate moieties, while titers declined for the highest glycosylation degree.<sup>9</sup> This led to selection of the conjugate with 17 carbohydrate moieties for Phase-1 clinical trials.

Of note, the above mentioned conjugates of  $\beta$ -(1,3)-glucans to 4 tyrosine residues of CRM<sub>197</sub> gave statistically similar antibody titers compared to higher levels of glycosylation at K,<sup>51</sup> although a certain trend of increased IgG titers was observed for a random conjugate with 17 glycan moieties. This suggests that in some cases few defined conjugation sites could be sufficient to raise an adequate immunogenicity.

The *Salmonella* O-antigen (composed of approximately 50 repeating units) has been able to provide robust immunogenicity even with a single attachment sites, depending on the targeted amino acid. The same applies to bioconjugates from *Shigella* or other bacterial O-antigens which contains oligosaccharide chains of ~10–20 repeating units. We can reason that lower degree of glycan incorporation might be compensated by the use of longer oligosaccharides, which express multiple copies of the minimal epitope. Therefore a balance of defined attachment sites and optimized saccharide length could give rise to highly immunogenic homogenous vaccines.

### 4.3 Alternative approaches

On the opposite direction go other recent strategies aiming at maximizing the exposition of short defined glycans by conjugation of sugar clusters or multivalent display around a variety of organic or inorganic nanoparticle cores. This approach, which has been proven fundamental to overcome the inherent poor immunogenicity of mammalian glycans as those decorating cancer cells or the viral surface<sup>7,54</sup> has been recently applied also for the improvement of antimicrobial glycoconjugates. Random conjugation *via* CuAAC of 360 copies of a synthetic tetrasaccharide epitope at the surface K residues of Qb virus-like bacteriophage particles has allowed achieving dramatic increase in the affinity of antibodies generated towards pneumococcal type 14 capsule (Fig. 5A).<sup>55</sup> Site-selective glycosylation of Qb virus-like bacteriophage particles has also been shown feasible by incorporation of the uAA homoallylglycine followed by




Fig. 5 Conjugation to AA residues of Q $\beta$  nanoparticles.

thiol-ene addition of 180 copies of thiolglycosides (Fig. 5B).<sup>19</sup> Nanoparticle systems could provide efficient presentation of small synthetic glycan epitopes.

## 5. Conclusions

Glycoconjugation has provided a key tool for the preparation of efficacious vaccines. New methods for producing the carbohydrate component have matured in the last decades, along with selective conjugation methods. Chemical synthesis combined to structural studies for the identification of the minimal antigenic polysaccharide portion responsible for the interaction with protective antibodies is providing relevant information for carbohydrate selection.

Combination of production of rationally defined carbohydrates either *in vitro* chemo-enzymatic or *in vivo* glycoengineering methods and selective conjugation holds the potential to design glycoconjugates with higher quality control standard, process reproducibility and pathogen free production. In addition to those features, synthetic carbohydrates specifically lack of bacterial contaminants.

A lot needs to be unravelled on the mechanism of action of glycoconjugates, particularly on the impact of the conjugation site on the protein peptides responsible for the T cell help. Therefore, selective conjugation can contribute also to a better understanding of the mode of action of this class of vaccines. Recently different novel designs have been allowed by progress in chemical modification of proteins, incorporation of unnatural amino acids and glycoengineering. Particularly, the latter approach has led different novel glycoconjugates to clinical trials. Synthetic methods for carbohydrate production are also maturing and a vaccine against *S. flexneri* 2a has recently completed a Phase-1 study.

While methods for selective conjugation of polysaccharides appear timely more feasible, factors effecting the immunogenic activity of fully homogeneous conjugates with defined glycan and attachment site (*e.g.* optimal sugar length and number of attachment sites) still need more profound studies.

We expect that the new designs based on selective glycoconjugation will become more and more employed for vaccine production leading to a new generation of innovative and improved vaccines.



## Conflicts of interest

FB and RA are employees of GSK group of companies.

## Acknowledgements

We acknowledge the European Union's Horizon 2020 research and innovation programme for funding work on this topic under the Marie Skłodowska-Curie grant agreement Glycovax No. 675671.

## Notes and references

- 1 F. Micoli, P. Costantino and R. Adamo, *FEMS Microbiol. Rev.*, 2018, **42**, 388–423.
- 2 O. T. Avery and W. F. Goebel, *J. Exp. Med.*, 1931, **54**, 437–447.
- 3 Q.-Y. Hu, F. Berti and R. Adamo, *Chem. Soc. Rev.*, 2016, **45**, 1691–1719.
- 4 E. De Gregorio and R. Rappuoli, *Nat. Rev. Immunol.*, 2014, **14**, 505–514.
- 5 F. Y. Avci, X. Li, M. Tsuji and D. L. Kasper, *Nat. Med.*, 2011, **17**, 1602–1609.
- 6 C. H. Jones, G. Zhang, R. Nayerhoda, M. Beitelshes, A. Hill, P. Rostami, Y. Li, B. A. Davidson, P. I. Knight and B. A. Pfeifer, *Sci. Adv.*, 2017, **3**, e1701797.
- 7 M. Marradi, F. Chiodo, I. Garcia and S. Penades, *Chem. Soc. Rev.*, 2013, **42**, 4728–4745.
- 8 V. Verez-Bencomo, V. Fernandez-Santana, E. Hardy, M. E. Toledo, M. C. Rodriguez, L. Heynngnezz, A. Rodriguez, A. Baly, L. Herrera, M. Izquierdo, A. Villar, Y. Valdes, K. Cosme, M. L. Deler, M. Montane, E. Garcia, A. Ramos, A. Aguilar, E. Medina, G. Torano, I. Sosa, I. Hernandez, R. Martinez, A. Muzachio, A. Carmenates, L. Costa, F. Cardoso, C. Campa, M. Diaz and R. Roy, *Science*, 2004, **305**, 522–525.
- 9 R. M. van der Put, T. H. Kim, C. Guerreiro, F. Thouron, P. Hoogerhout, P. J. Sansonetti, J. Westdijk, M. Stork, A. Phalipon and L. A. Mulard, *Bioconjugate Chem.*, 2016, **27**, 883–892.
- 10 H. S. Hahm, M. K. Schlegel, M. Hurevich, S. Eller, F. Schuhmacher, J. Hofmann, K. Pagel and P. H. Seeberger, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, E3385–E3389.
- 11 D. Oldrini, T. Fiebig, M. R. Romano, D. Proietti, M. Berger, M. Tontini, R. De Ricco, L. Santini, L. Morelli, L. Lay, R. Gerardy-Schahn, F. Berti and R. Adamo, *ACS Chem. Biol.*, 2018, **13**, 984–994.
- 12 Z. Hu, A. F. Bongat White and L. A. Mulard, *Chem. – Asian J.*, 2017, **12**, 419–439.
- 13 N. Ravenscroft, M. A. Haeuptle, M. Kowarik, F. S. Fernandez, P. Carranza, A. Brunner, M. Steffen, M. Wetter, S. Keller, C. Ruch and M. Wacker, *Glycobiology*, 2016, **26**, 51–62.
- 14 N. Ravenscroft, P. Costantino, P. Talaga, R. Rodriguez and W. Egan, *Vaccine Analysis: Strategies, Principles, and Control*, Springer Nature, Switzerland AG, 2015, pp. 301–381.
- 15 R. Adamo, A. Nilo, B. Castagner, O. Boutureira, F. Berti and G. J. Bernardes, *Chem. Sci.*, 2013, **4**, 2995–3008.
- 16 R. Dagan, J. Poolman and C. A. Siegrist, *Vaccine*, 2010, **28**, 5513–5523.
- 17 S. Crotti, H. Zhai, J. Zhou, M. Allan, D. Proietti, W. Pansegrau, Q. Y. Hu, F. Berti and R. Adamo, *ChemBioChem*, 2014, **15**, 836–843.
- 18 M. J. Matos, B. L. Oliveira, N. Martínez-Sáez, A. Guerreiro, P. M. S. D. Cal, J. Bertoldo, M. Maneiro, E. Perkins, J. Howard, M. J. Deery, J. M. Chalker, F. Corzana, G. Jiménez-Osés and G. J. L. Bernardes, *J. Am. Chem. Soc.*, 2018, **140**, 4004–4017.
- 19 E. J. Grayson, G. J. Bernardes, J. M. Chalker, O. Boutureira, J. R. Koeppel and B. G. Davis, *Angew. Chem., Int. Ed.*, 2011, **50**, 4127–4132.
- 20 O. Boutureira, N. Martinez-Saez, K. M. Brindle, A. A. Neves, F. Corzana and G. J. L. Bernardes, *Chem. – Eur. J.*, 2017, **23**, 6483–6489.
- 21 B. Lee, S. Sun, E. Jimenez-Moreno, A. A. Neves and G. J. L. Bernardes, *Bioorg. Med. Chem.*, 2018, **28**, 2403–2407.
- 22 J. M. Chalker, S. B. Gunnoo, O. Boutureira, S. C. Gerstberger, M. Fernández-González, G. J. L. Bernardes, L. Griffin, H. Hailu, C. J. Schofield and B. G. Davis, *Chem. Sci.*, 2011, **2**, 1666.
- 23 A. M. Freedy, M. J. Matos, O. Boutureira, F. Corzana, A. Guerreiro, P. Akkapeddi, V. J. Somovilla, T. Rodrigues, K. Nicholls, B. Xie, G. Jimenez-Oses, K. M. Brindle, A. A. Neves and G. J. L. Bernardes, *J. Am. Chem. Soc.*, 2017, **139**, 18365–18375.
- 24 G. Stefanetti, Q. Y. Hu, A. Usera, Z. Robinson, M. Allan, A. Singh, H. Imase, J. Cobb, H. Zhai, D. Quinn, M. Lei, A. Saul, R. Adamo, C. A. MacLennan and F. Micoli, *Angew. Chem., Int. Ed.*, 2015, **54**, 13198–13203.
- 25 H. Ban, J. Gavrilyuk and C. F. Barbas, *J. Am. Chem. Soc.*, 2010, **132**, 1523–1525.
- 26 Q.-Y. Hu, M. Allan, R. Adamo, D. Quinn, H. Zhai, G. Wu, K. Clark, J. Zhou, S. Ortiz, B. Wang, E. Danieli, S. Crotti, M. Tontini, G. Brogioni and F. Berti, *Chem. Sci.*, 2013, **4**, 3827–3832.
- 27 D. Rabuka, *Curr. Opin. Chem. Biol.*, 2010, **14**, 790–796.
- 28 C. W. Lin and A. Y. Ting, *J. Am. Chem. Soc.*, 2006, **128**, 4542–4543.
- 29 S. Jeger, K. Zimmermann, A. Blanc, J. Grunberg, M. Honer, P. Hunziker, H. Struthers and R. Schibli, *Angew. Chem., Int. Ed.*, 2010, **49**, 9995–9997.
- 30 K. Wals and H. Ovaas, *Front. Chem.*, 2014, **2**, DOI: 10.3389/fchem.2014.00015.
- 31 T. Machida, K. Lang, L. Xue, J. W. Chin and N. Winssinger, *Bioconjugate Chem.*, 2015, **26**, 802–806.
- 32 J. F. Zawada, G. Yin, A. R. Steiner, J. Yang, A. Naresh, S. M. Roy, D. S. Gold, H. G. Heinsohn and C. J. Murray, *Biotechnol. Bioeng.*, 2011, **108**, 1570–1578.
- 33 M. Wacker, D. Linton, P. G. Hitchen, M. Nita-Lazar, S. M. Haslam, S. J. North, M. Panico, H. R. Morris, A. Dell, B. W. Wren and A. Markus, *Science*, 2002, **298**, 1790–1793.
- 34 M. Kowarik, N. M. Young, S. Numao, B. L. Schulz, I. Hug, N. Callewaert, D. C. Mills, D. C. Watson, M. Hernandez, J. F. Kelly, M. Wacker and M. Aebi, *EMBO J.*, 2006, **25**, 1957–1966.



- 35 S. Villeneuve, H. Souchon, M. M. Riottot, J. C. Mazie, P. Lei, C. P. Glaudemans, P. Kovac, J. M. Fournier and P. M. Alzari, *Proc. Natl. Acad. Sci. U. S. A.*, 2000, **97**, 8433–8438.
- 36 F. Carboni, R. Adamo, M. Fabbrini, R. De Ricco, V. Cattaneo, B. Brogioni, D. Veggi, V. Pinto, I. Passalacqua, D. Oldrini, R. Rappuoli, E. Malito, I. Y. R. Margarit and F. Berti, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, 5017–5022.
- 37 B. Vulliez-Le Normand, F. A. Saul, A. Phalipon, F. Belot, C. Guerreiro, L. A. Mulard and G. A. Bentley, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 9976–9981.
- 38 D. Safari, H. A. Dekker, J. A. Joosten, D. Michalik, A. C. de Souza, R. Adamo, M. Lahmann, A. Sundgren, S. Oscarson, J. P. Kamerling and H. Snippe, *Infect. Immun.*, 2008, **76**, 4615–4623.
- 39 C. Anish, B. Schumann, C. L. Pereira and P. H. Seeberger, *Chem. Biol.*, 2014, **21**, 38–50.
- 40 P. W. Anderson, M. E. Pichichero, R. A. Insel, R. Betts, R. Eby and D. H. Smith, *J. Immunol.*, 1986, **137**, 1181–1186.
- 41 P. W. Anderson, M. E. Pichichero, E. C. Stein, S. Porcelli, R. F. Betts, D. Connuck, D. Korones, R. A. Insel, J. M. Zahradnik and R. Eby, *J. Immunol.*, 1989, **142**, 2464–2468.
- 42 J. Y. Baek, A. Geissner, D. C. K. Rathwell, D. Meierhofer, C. L. Pereira and P. H. Seeberger, *Chem. Sci.*, 2017, **9**, 1279–1288.
- 43 A. Nilo, L. Morelli, I. Passalacqua, B. Brogioni, M. Allan, F. Carboni, A. Pezzicoli, F. Zerbini, D. Maione, M. Fabbrini, M. R. Romano, Q. Y. Hu, I. Margarit, F. Berti and R. Adamo, *ACS Chem. Biol.*, 2015, **10**, 1737–1746.
- 44 A. Nilo, I. Passalacqua, M. Fabbrini, M. Allan, A. Usera, F. Carboni, B. Brogioni, A. Pezzicoli, J. Cobb, M. R. Romano, I. Margarit, Q. Y. Hu, F. Berti and R. Adamo, *Bioconjugate Chem.*, 2015, **26**, 1839–1849.
- 45 A. Nilo, M. Allan, B. Brogioni, D. Proietti, V. Cattaneo, S. Crotti, S. Sokup, H. Zhai, I. Margarit, F. Berti, Q. Hu and R. Adamo, *Bioconjugate Chem.*, 2014, **25**, 2105–2111.
- 46 N. Martinez-Saez, S. Sun, D. Oldrini, P. Sormanni, O. Boutoureira, F. Carboni, I. Companon, M. Deery, M. Vendruscolo, F. Corzana, R. Adamo and G. J. L. Bernardes, *Angew. Chem., Int. Ed.*, 2017, **56**, 14963–14967.
- 47 M. Wetter, M. Kowarik, M. Steffen, P. Carranza, G. Corradin and M. Wacker, *Glycoconjugate J.*, 2013, **30**, 511–522.
- 48 M. Wacker, L. Wang, M. Kowarik, M. Dowd, G. Lipowsky, A. Faridmoayer, K. Shields, S. Park, C. Alaimo, K. A. Kelley, M. Braun, J. Quebatte, V. Gambillara, P. Carranza, M. Steffen and J. C. Lee, *J. Infect. Dis.*, 2014, **209**, 1551–1561.
- 49 C. F. Hatz, B. Bally, S. Rohrer, R. Steffen, S. Kramme, C. A. Siegrist, M. Wacker, C. Alaimo and V. G. Fonck, *Vaccine*, 2015, **33**, 4594–4601.
- 50 A. Huttner, C. Hatz, G. van den Dobbelen, D. Abbanat, A. Hornacek, R. Frölich, A. M. Dreyer, P. Martin, T. Davies, K. Fae, I. van den Nieuwenhof, S. Thoelen, S. de Vallière, A. Kuhn, E. Bernasconi, V. Viereck, T. Kavvadias, K. Kling, G. Ryu, T. Hülner, S. Gröger, D. Scheiner, C. Alaimo, S. Harbarth, J. Poolman and V. G. Fonck, *Lancet Infect. Dis.*, 2017, **17**, 528–537.
- 51 R. Adamo, Q.-Y. Hu, A. Torosantucci, S. Crotti, G. Brogioni, M. Allan, P. Chiani, C. Bromuro, D. Quinn, M. Tontini and B. Berti, *Chem. Sci.*, 2014, **5**, 4302–4311.
- 52 V. Pozsgay, C. Chu, L. Pannell, J. Wolfe, J. B. Robbins and R. Schneerson, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 5194–5197.
- 53 B. Schumann, K. Reppe, P. Kaplonek, A. Wahlbrink, C. Anish, M. Witzernath, C. L. Pereira and P. H. Seeberger, *ACS Cent. Sci.*, 2018, **4**, 357–361.
- 54 F. Peri, *Chem. Soc. Rev.*, 2013, **42**, 4543–4556.
- 55 Z. Polonskaya, S. Deng, A. Sarkar, L. Kain, M. Comellas-Aragones, C. S. McKay, K. Kaczanowska, M. Holt, R. McBride, V. Palomo, K. M. Self, S. Taylor, A. Irimia, S. R. Mehta, J. M. Dan, M. Brigger, S. Crotty, S. P. Schoenberger, J. C. Paulson, I. A. Wilson, P. B. Savage, M. G. Finn and L. Teyton, *J. Clin. Invest.*, 2017, **127**, 1491–1504.

